Jörg P. Adamczewski

We don’t have enough information about this author to calculate their statistics. If you think this is an error let us know.
Learn More
Monoclonal antibody (mAb) therapeutics have tremendous potential to benefit patients with lung diseases, for which there remains substantial unmet medical need. To capture the current state of mAb research and development in the area of respiratory diseases, the Research Center of Respiratory Diseases (CEPR-INSERM U1100), the Laboratory of Excellence(More)
  • 1